Skip to main content

Pfizer and Odyssey Thera Expand Cell-Based Drug-Profiling Collaboration

NEW YORK (GenomeWeb News) – Pfizer will use Odyssey Thera’s cell-based protein-fragment complementation assay (PCA) technology to evaluate the selectivity of Pfizer compounds, Odyssey said today.
 
Under the terms of the agreement, Odyssey will receive an upfront payment, research and capital expenditure funding, and success-based milestone payments. Further financial details were not disclosed.
 
The current research collaboration will focus on “large numbers” of Pfizer chemical leads and drug candidates from multiple therapeutic areas, Odyssey said. Odyssey and Pfizer will use the PCA technology and other assays based on automated microscopy to measure changes in cellular signaling networks in response to Pfizer compounds.
 

The agreement expands upon a May 2005 collaboration between the companies to profile certain Pfizer compounds using the PCA technology.

The Scan

Call to Look Again

More than a dozen researchers penned a letter in Science saying a previous investigation into the origin of SARS-CoV-2 did not give theories equal consideration.

Not Always Trusted

In a new poll, slightly more than half of US adults have a great deal or quite a lot of trust in the Centers for Disease Control and Prevention, the Hill reports.

Identified Decades Later

A genetic genealogy approach has identified "Christy Crystal Creek," the New York Times reports.

Science Papers Report on Splicing Enhancer, Point of Care Test for Sexual Transmitted Disease

In Science this week: a novel RNA structural element that acts as a splicing enhancer, and more.